Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance

FEMS Yeast Research

Volumn 6, Issue 7, 2006, Pages 1063-1073

  Jabra Rizk, Mary Ann ^a,b   Shirtliff, Mark ^a,b   James, Cathy ^a   Meiller, Timothy ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biofilm; Candida albicans; Candida dubliniensis; Farnesol; Fluconazole resistance

Indexed keywords

FARNESOL; FLUCONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOFILM; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CELL MEMBRANE; CONFERENCE PAPER; CONFOCAL LASER MICROSCOPY; DRUG EFFECT; DRUG POTENTIATION; FUNGAL VIRULENCE; GENE DISRUPTION; NONHUMAN;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; DRUG RESISTANCE, FUNGAL; ETHIDIUM; FARNESOL; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS;

CANDIDA ALBICANS; CANDIDA DUBLINIENSIS;

EID: 33750026798     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2006.00121.x     Document Type: Conference Paper

References (63)

1. Baillie GS & Douglas LJ (1999a) Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol 310: 644-656.
2. Baillie GS & Douglas LJ (1999b) Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 48: 671-679.
3. Baillie GS & Douglas LJ (2000) Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 46: 397-403.
4. Borg-von Zepelin M, Niederhaus T, Gross U, Seibold M, Monod M & Tintelnot K (2002) Adherence of different Candida dubliniensis isolates in the presence of fluconazole. AIDS 16: 1237-1244.
5. Brandt ME, Harrison LH, Pass M, Sofair AN, Huie S, Li R-K, Morrison CJ, Warnock DW & Hajjeh RA (2000) Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis 6: 1-6.
6. Brehm-Stecher BF & Johnson EA (2003) Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, apritone. Antimicrob Agents Chemother 47: 3357-3360.
7. Brown DM, Jabra-Rizk MA, Falkler WA, Baqui AAMA & Meiller TF (2000) Identification of Candida dubliniensis in a prospective study of HIV-seropositive pediatric dental patients. J Pediatr Dentistry 22: 234-238.
8. Cao YY, Cao YB, Xu Z, Ying K, Li Y, Xie Y, Zhu ZY, Chen WS & Jiang YY (2005) cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 49: 584-589.
9. Chandra J, Kuhn DM, Mulherjee PK, Hoyer LL, McCormick T & Ghannoum MA (2001a) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394.
10. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ & Ghannoum MA (2001b) Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 80: 903-908.
11. Chen H, Fumita M, Feng Q, Clardy J & Fink GR (2004) Tyrosol is a quorum-sensing molecule in Candida albicans. Proc Natl Acad Sci USA 101: 5048-5052.
12. Davey ME & O'Toole GA (2000) Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 64: 847-867.
13. Donlan RM (2002) Biofilms: microbial life on surfaces. Emerg Infect Dis 8: 1-19.
14. Donlan RM & Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193.
15. Douglas LJ (2003) Candida biofilms and their role in infection. Trends Microbiol 11: 30-36.
16. Dumitru R, Hornby JM & Nickerson KW (2004) Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob Agents Chemother 48: 2350-2354.
17. Edwards PA & Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68: 157-185.
18. Enjalbert B &Whiteway M (2005) Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth. Eukaryotic Cell 4: 1203-1210.
19. García-Sánchez S, Aubert S, Iraqui I, Janbon G, Ghigo J-M & d'Enfert C (2004) Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryotic Cell 3: 536-545.
20. Hornby JM & Nickerson KW (2004) Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 48: 2305-2307.
21. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P & Nickerson KW (2001) Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 67: 2982-2992.
22. Hornby JM, Kebaara BW & Nickerson KW (2003) Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zargozic acid B. Antimicrob Agents Chemother 47: 2366-2369.
23. Jabra-Rizk MA, Baqui AAMA, Kelley JI, Falkler WA Jr, Merz WG & Meiller TF (1999a) Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 37: 321-326.
24. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Kelley JI, Baqui AAMA & Meiller TF (1999b) Candida dubliniensis and Candida albicans display surface variations consistent with observed intergeneric coaggregation. Rev Iberoam Micol 16: 8-14.
25. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AAMA, Kelley JI & Meiller TF (2000) Retrospective identification of Candida dubliniensis among Candida albicans clinical laboratory isolates from HIV and non-HIV individuals. J Clin Microbiol 38: 2423-2426.
26. Jabra-Rizk MA, Falkler WF Jr, Merz WG, Baqui AAMA, Kelley JI & Meiller TF (2001a) Cell surface hydrophobicity-associated adherence of Candida dubliniensis to human buccal epithelial cells. Rev Iberam Micol 18: 17-22.
27. Jabra-Rizk MA, Falkler WA Jr, Merz WG & Meiller TF (2001b) New assay for measuring cell surface hydrophobicity of Candida dubliniensis and Candida albicans. Clin Diagn Lab Immunol 8: 585-587.
28. Jabra-Rizk MA, Ferreira SMS, Sabet M, Falkler WA, Merz WG & Meiller TF (2001c) Recovery of Candida dubliniensis and other yeast from human immunodeficiency virus-associated periodontal lesions. J Clin Microbiol 39: 4520-4522.
29. Jabra-Rizk MA, Falkler WA Jr & Meiller TF (2004) Fungal biofilms and drug resistance. Emerg Infect Dis 10: 14-19.
30. Jabra-Rizk MA, Johnson JK, Forrest G, Mankes K, Meiller TF & Venezia RA (2005) Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis 41: 1064-1067.
31. Kim JO, Garofalo L, Blecker-Shelly D & McGowan KL (2003) Candida dubliniensis infections in a pediatric population: retrospective identification from clinical laboratory isolates of Candida albicans. J Clin Microbiol 41: 3354-3357.
32. Kirkpatrick WR, Lopez-Ribot JL, McAtee RK & Patterson TF (2000) Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions. J Clin Microbiol 38: 902-904.
33. Kruppa M, Krom BP, Chauhan N, Bambach AV, Cihlar RL & Calderone RA (2004) The two-component signal transduction protein Chk1p regulates quorum sensing in Candida albicans. Eukaryotic Cell 3: 1062-1065.
34. Lewis K (2001) Riddle of biofilm resistance. Antimicrob Agents Chemother 45: 999-1007.
35. Machida K, Tanaka T, Fujita K & Taniguchi M (1998) Farnesol-induced generation of reactive oxygen species via indirect inhibition of the mitochondrial electron transport chain in the yeast Saccharomyces cerevisiae. J Bacteriol 180: 4460-4465.
36. Meis JFGM, Ruhnke M, De Pauw BE, Odds FC, Siegert W & Verweij PE (1999) Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5: 150-153.
37. Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB & Coleman DC (1997) Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 41: 617-623.
38. Moran GP, Sanglard D, Donnelly SM, Shanley D, Sullivan DJ & Coleman DC (1998) Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 42: 1819-1830.
39. Moran G, Sullivan DJ, Morschhauser J & Coleman DC (2002) The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance. Animicrob Agents Chemother 46: 2829-2941.
40. Mosel DD, Dumitru R, Hornby JM, Atkin AL & Nickerson KW (2005) Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 71: 4938-4940.
41. National Committee for Clinical Laboratory Standards (1997) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. National Committee for Clinical Laboratory Standards, Wayne, PA.
42. Oh K-B, Miyazawa H, Naito T & Matsuoka H (2001) Purification and characterization of an autoregulatory substance capable of regulating the morphological transition in Candida albicans. Proc Natl Acad Sci USA 98: 4664-4668.
43. O'Toole GA, Kaplan HB & Kolter R (2000) Biofilm formation as microbial development. Annu Rev Microbiol 54: 49-79.
44. Plochocka D, Karst F, Swiezewska E & Szkopinska A (2000) The role of ERG20 gene (encoding yeast farnesyl diphosphate synthase) mutation in long dolichol formation. Molecular modeling of FPP syntase. Biochimie 82: 733-738.
45. Ramage G, Vande Walle K, Wickes BL & López-Ribot JL (2001) Biofilm formation by Candida dubliniensis. J Clin Microbiol 39: 3234-3240.
46. Ramage G, Bachmann S, Patterson TF, Wickes BL & López-Ribot JL (2002a) Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 49: 973-980.
47. Ramage G, Saville SP, Wickes BL & López-Ribot JL (2002b) Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 68: 5459-5463.
48. Ramage G, VandeWalle K, Bachmann S, Wickes BL & López-Ribot JL (2002c) In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46: 3634-3636.
49. Sato T, Watanabe T, Mikami T & Matsumoto T (2004) Farnesol, a morphogenetic autoregulatory substance in the dimorphic fungus Candida albicans, inhibits hyphae growth through suppression of a mitogen-activated protein kinase cascade. Biol Pharmacy Bull 27: 751-752.
50. Saville SP, Lazzell AL, Monteagudo C & López-Ribot JL (2002) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryotic Cell 2: 1053-1060.
51. Sebti A, Kiehn TE, Perlin D, Chaturvedi V, Wong M, Doney A, Park S & Sepkowitz KA (2001) Candida dubliniensis at a cancer center. Clin Infect Dis 32: 1034-1038.
52. Shchepin R, Hornby JM, Burger E, Niessen T, Dussault P & Nickerson KW (2003) Quorum sensing in Candida albicans: probing farnesol's mode of action with 40 natural and synthetic farnesol analogs. Chem Biol 10: 743-750.
53. Shchepin R, Dumitru R, Nickerson KW, Lund M & Dussault PH (2005) Biologically active fluorescent farnesol analogs. Chem Biol 12: 639-641.
54. Song L (2003) Detection of farnesyl diphosphate accumulation in yeast ERG9 mutants. Anal Biochem 317: 180-185.
55. Staib P, Kretschmar M, Nichterlein T, Kohler G, Michel S, Hof H, Hacker J & Morschhauser J (1999) Host-induced, stage-specific virulence gene activation in Candida albicans during infection. Mol Microbiol 32: 533-546.
56. Sullivan D & Coleman D (1997) Candida dubliniensis an emerging opportunistic pathogen. Curr Top Med Mycol 8: 15-25.
57. Sullivan D, Westerneng T, Haynes KA, Bennett D & Coleman D (1995) Candida dubliniensis sp. nov. = phenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 141: 1507-1521.
58. Sullivan D, Haynes K, Bille J, Boerlin P, Rodero L, Lloyd S, Henman M & Coleman D (1997) Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 35: 960-964.
59. Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C & Coleman DC (2004) Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 4: 369-376.
60. Szkopińska A, Grabińska K, Delourme D, Karst F, Rytka J & Palamarczyk G (1997) Polyprenol formation in the yeast Saccharomyces cerevisiae: effect of farnesyl diphosphate synthase overexpression. J Lipid Res 38: 962-968.
61. White TC (1997) Increased mRNA levels of ERG 16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487.
62. White TC, Marr KA & Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382-402.
63. White TC, Holleman S, Dy F, Mirels LF & Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713.